Molecular Targeted Therapy of Hepatocellular Carcinoma

Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.

Hepatocellular carcinoma is a malignant tumor responsible for approximately 600,000-700,000 deaths worldwide, and is becoming more prevalent not only in South-East Asia and Africa, but also in Western countries; therefore, interest in hepatocellular carcinoma has mounted in recent years in the West, where little or no interest was evident 10-20 years ago.

Targeted Therapy in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide, as well as a common cause of cancer-related death. HCC frequently occurs in the setting of a diseased cirrhotic liver and many patients present at an advanced stage of disease. Together with a poor functional status, this often precludes the use of systemic therapy, especially conventional cytotoxic drugs. Moreover, HCC i...

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar ) was approved in Japan for ‘unresectable hepatocellular carcinoma (HCC)’, and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III ra...

Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar ) was approved in Japan for ‘unresectable hepatocellular carcinoma (HCC)’, and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III ra...